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ABSTRACT 
Background: Opioids commonly used for pain relief may lead to hypogonadism, which is 
characterised by suppression of production of the gonadotropin releasing hormone (GnRH) 
resulting in inadequate production of sex hormones. 
Objective: To highlight the effects of opioids on the endocrine system and the development 
of hypogonadism. 
Method: A narrative literature review of studies investigating hypogonadism in patients 
undertaking opioid therapy was carried out. MEDLINE, EMBASE and Cochrane Library 
were searched for relevant articles using a combination of both indexing and free text terms. 
Results: The suppression of GnRH leading to a decrease in sex hormones has been described 
as the principal mechanism of opioid induced hypogonadism. However, there is no consensus 
on the threshold for the clinical diagnosis of hypogonadism. 
Conclusion: Evidence indicates that chronic opioid use can lead to hypogonadism. Clinicians 
should be aware of symptomatology associated with hypogonadism and should regularly 
monitor patients with appropriate laboratory investigations. 
  
  
INTRODUCTION 
The hypothalamic-pituitary-gonadal (HPG) axis plays an important role in the development 
and regulation of the reproductive system. Gonadotropin releasing hormone (GnRH) is 
secreted by the hypothalamus in a pulsatile fashion, which regulates the release of luteinising 
hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. In males, LH 
regulates the number and function of Leydig cells in the testis and hence the production of 
testosterone, whereas FSH stimulates Sertoli cell division and spermatogenesis. In females, 
FSH stimulates the differentiation of granulosa cells in the ovaries and LH stimulates the 
production of androgens by the theca cells, and of oestradiol and progesterone by mature 
granulosa cells and corpus luteal cells. Testosterone in males and oestradiol in females have a 
negative feedback on the pituitary inhibiting gonadotropin secretion. Opioids and prolactin 
reduce the pulsatile activity of GnRH inhibiting LH and FSH secretion from the pituitary.[1] 
Pharmacological analgesic opioids are derived from the medicinal poppy plant Papaver 
Somniferum. These analgesics have been used for centuries to relieve acute and chronic 
pain.[2] Common side-effects of these drugs include sedation, dizziness, constipation, urinary 
retention, itchiness, nausea and respiratory depression.[3,4] Hypogonadism is one of the least 
recognised and investigated side-effect of opioids.[5] Although patients are generally 
forthcoming in reporting health related complaints to physicians, some patients may associate 
symptoms of hypogonadism such as decreased libido, tiredness, loss of muscle mass and 
strength to the pain condition or may not feel comfortable discussing some of the symptoms 
with the treating physician, therefore making it difficult to identify hypogonadism without 
routine laboratory investigations.[6] 
The aim of this review is to appraise the effects of opioids on the endocrine system and the 
potential link between opioids and hypogonadism. 
 
METHODS 
A review of studies examining hypogonadism in patients undertaking opioids was carried 
out. MEDLINE (Ovid), EMBASE (Ovid) and the Cochrane Library (Wiley) databases were 
searched for relevant articles published up to May 6th, 2016. A combination of both indexing 
and free text terms was used including opioids, hypogonadism, testosterone, endocrine, 
androgen, luteinising hormone and follicle stimulating hormone. Studies were selected for 
  
inclusion if they investigated hypogonadism, low testosterone or low oestrogen in chronic 
pain patients undertaking opioid therapy. The search was restricted to articles published in 
English. A hand-search of reference lists of studies meeting the inclusion criteria was also 
performed. 
DIAGNOSIS OF HYPOGONADISM 
Male hypogonadism may result from either primary testicular failure (primary 
hypogonadism) or secondary testicular failure (secondary hypogonadism) due to 
hypothalamic or pituitary disease. Primary hypogonadism is characterised by low serum 
testosterone and high serum LH and FSH concentrations, whereas secondary hypogonadism 
is characterised by low serum testosterone and inappropriately low serum LH and FSH. In 
females, primary ovarian failure results in low oestrogen levels and elevated FSH, while in 
secondary hypogonadism, low oestrogen and FSH levels are observed. 
EFFECTS OF OPIOIDS ON THE ENDOCRINE SYSTEM 
Male hypogonadism following the use of opioids 
Opioid-induced hypogonadism is characterised by low serum levels of testosterone, LH and 
FSH which is associated with decreased libido, impotence, reduced body hair, poor muscle 
strength and fatigue.[7-10] Several studies have indicated that opioids result in low levels of 
testosterone and hypogonadism in men regardless of the route of administration, i.e. whether 
oral, intrathecal or transdermal (Table 1).[11-15] It has also been reported that the use of 
intrathecal opioids in men causes suppression of both LH and FSH and consequently serum 
testosterone levels leading to hypogonadism.[16] Amongst the various opioids prescribed, 
studies have suggested that buprenorphine has one of the least inhibitory effects on sex 
hormones due to its nature as a partial ʮ agonist.[17,18] 
It has been suggested that patients on long-term opioids are at an increased risk of developing 
hypogonadism compared to those treated with short term opioids.[18,19] These authors 
suggested that the suppressive effect by long acting opioids could be due to the sustained 
serum drug levels, whereas serum levels with the short acting opioids may vary throughout 
the day allowing intermittent GnRH and LH suppression.  
Although low serum testosterone is the principle reason for opioid-induced hypogonadism, it 
is important to consider other factors which may affect testosterone levels.[11,20] For 
  
example, it is well established that testosterone levels progressively decline with age and may 
be affected by smoking, lack of physical exercise and high BMI.[21-24] 
 
Study Type of 
Study 
Intervent
ion 
Participa
nts 
Results Conclusion 
Abs et al.[12] Retrospective 
study 
Intratheca
l opioids 
29 men Decrease libido in 23 
of 24 men was 
observed. Serum 
testosterone levels 
were below 9 nmol/L 
in 25 men of 29 men. 
Majority of the 29 
men in the study 
receiving 
Intrathecal opioids 
developed 
hypogonadotropic 
hypogonadism. 
Aloisi et 
al.[13] 
Cross 
sectional 
study 
Intratheca
l 
opioids 
4 men 
short term 
and 6 men 
long term  
Testosterone levels 
were observed to be 
low in day 7 and 
continued to decrease 
until day 23 in short 
term opioid treated 
men (morphine 0.5-1.2 
mg/day). In long term 
opioid (0.5-2.5 
mg/day), similar effect 
of reduced testosterone 
levels was observed 
(0.99 VS 2.47ng/ml). 
The observations 
indicate that men on 
long term opioids 
have significantly 
reduced testosterone 
levels in 
comparison to men 
on short term 
Intrathecal opioids. 
The study suggests 
that the testosterone 
levels were 
observed to be in 
the range of those 
underlying 
hypogonadism. 
Duarte et 
al.[16] 
Cross 
sectional 
study 
Intratheca
l opioids 
20 men 17 men had 
biochemical 
hypogonadism and 15 
had free testosterone 
levels of <180 pmol/L 
and 2 with 180pmol/L 
and 250 pmol/L. 
The observation 
suggests an 
association between 
intrathecal opioids 
and hypogonadism, 
with 85% of men 
developing 
biochemical 
hypogonadism. 
Fraser et 
al.[15] 
Cross 
sectional 
study 
Oral 
opioids 
12 men 75% of 12 men were 
identified to have a 
high prevalence of 
hypogonadism. 83% of 
men had total 
testosterone levels 
below the age specific 
range.   
The study 
demonstrated that 
long term oral 
opioids for chronic 
pain had a high 
prevalence rate of 
hypogonadism in 
men. 
Finch et al.[11] Cross 
sectional 
study 
Intratheca
l 
opioids 
20 men  
 
Testosterone levels 
were found to be 
below the normal 
range of 10 to 35 
nmol/L (4.9 ± 1.1 
nmol/L) and was 
Gonadotropin levels 
were observed to be 
low in male patients 
suggesting 
testosterone 
suppression in the 
Table 1: Studies investigating opioid induced hypogonadism in men 
  
significantly lower 
than the male control 
group (12.2 ± 1.6 
nmol/L) 
central inhibition of 
hypothalamic 
GnRH or FSH and 
LH. Men had clear 
evidence of low 
levels of serum 
testosterone.   
Rubinstein et 
al.[18] 
Retrospective 
cohort study 
Short 
term and 
long term 
opioids 
81 men 745 of men were found 
to be hypogonadal on 
long term opioids in 
comparison to 345 of 
men that were on short 
term opioids that were 
diagnosed as 
hypogonadal. 
High prevalence of 
hypogonadism was 
observed in opioid 
users according to 
the duration of the 
use of opioids. 
 
Female hypogonadism following the use of opioids 
Several studies have shown that women may also be at risk of developing hypogonadism 
(Table 2).[12,15,25] Symptoms include amenorrhea, oligomenorrhea, failure to conceive and 
hot flushes.[15] 
Fraser et al. showed that 21% of premenopausal women treated with opioids for longer than a 
year developed menstrual cycle abnormalities, such as oligomenorrhea and amenorrhea.[15] 
In a study of 32 women treated with intrathecal opioids, 22 women noted a decrease in libido 
and 7 developed irregular menstrual cycles.[12] In the same study, 18 postmenopausal 
women had significantly lower serum levels of LH and FSH than controls. It has also been 
reported that LH and FSH were 30% lower in premenopausal and 70% lower in 
postmenopausal women consuming sustained-action oral or transdermal opioids.[25] 
Bawor et al. found no effect from opioids, including methadone, on testosterone levels in 
women.[20] However, Daniell et al. observed that testosterone and dehydroepiandrosterone 
sulfate (DHEA-S) levels are lower in opioid-consuming women compared to controls 
indicating impaired adrenal androgen production.[25] 
 
 
 
 
 
  
Study Type of 
Study 
Interventi
on 
Participa
nts 
Results Conclusion 
Abs et al.[12] Retrospective 
study 
Intrathecal 
opioids 
44 women Decreased libido was 
present in 22 out of 32 
women receiving 
opioids. All 18 
postmenopausal 
females were observed 
to have decreased 
serum LH levels 
(P<0.001) and FSH 
levels (P=0.012). 
All women in the 
opioid group 
developed 
hypogonadotropic 
hypogonadism with 
15% developing 
central 
hypocorticism and 
15% developing 
growth hormone 
deficiency.  
Aloisi et al.[13] Cross 
sectional 
study 
Intrathecal 
opioids 
16 women 
short term 
and 18 
women 
long term 
No significant changes 
were detected in 
testosterone levels in 
women on short term 
opioids (morphine 0.5-
1.2 mg/day), although 
low levels were present 
on day 7, 14 and 23. 
Long term opioids 
(0.5-2.5 mg/day) did 
not show any 
difference and the 
results were 
comparable to control. 
Observations in the 
study demonstrated 
that opioids did not 
have a significant 
effect on 
testosterone levels 
in women on short 
term or long term 
opioids. 
Daniell[25] Cross 
sectional 
study 
Oral and 
Transderm
al opioids 
115 
women 
Testosterone, 
oestradiol and 
dehydroepiandrosteron
e sulphate were 48-
57% lower in the 
opioid group in 
comparison to the 
control group (P< .01-
.05). LH and FSH were 
30% lower in 
premenopausal women 
and 70% lower in 
postmenopausal 
women. 
Oophorectomised 
women not consuming 
oestrogen, free 
testosterone levels 
were 39% lower in 
opioid consumers. 
The observations 
suggest a decrease 
in adrenal androgen 
levels in most 
women consuming 
sustained action 
oral or transdermal 
opioids. 
Fraser et al.[15] Cross 
sectional 
study 
Oral 
opioids 
14 women 21% of 14 
premenopausal women 
indicated 
hypogonadism with 
reported amenorrhea. 
Women that underwent 
hysterectomy had 
Hypogonadism in 
women was based 
on self reporting of 
amenorrhoea. No 
major findings were 
present of chronic 
opioid effect on 
Table 2: Studies investigating opioid induced hypogonadism in women 
  
oestradiol levels of 349 
pmol/L; therefore the 
prevalence of 
hypogonadism was 
23%.  
menstrual cycle in 
women. 
Finch et al.[11] Cross 
sectional 
study  
Intrathecal 
opioids 
29 women 
 
Median oestradiol in 
premenopausal women 
were 125 pmol/l. FSH 
levels were 2U/L and 
LH levels 1U/L. Whilst 
postmenopausal 
women all had normal 
range of oestradiol. 
FSH (p = 0.0037) and 
LH (p = 0.0024) levels 
in women were 
significantly lower in 
the intrathecal opioid 
group in comparison to 
the control group. 
Intrathecal opioids 
showed low levels 
of oestrogen in 
women in addition 
to low levels in 
pituitary 
gonadotropins 
suggesting the 
development of 
hypogonadism. This 
study demonstrated 
small doses of 
intrathecal opioids 
have a profound 
effect on 
hypothalamic 
pituitary gonadal 
axis. 
 
CONSIDERATIONS 
The diagnosis of hypogonadism 
The most widely accepted parameter to establish the presence of hypogonadism in men is the 
measurement of serum total testosterone. The Endocrine Society defines hypogonadism as a 
failure of the testis to produce physiological levels of testosterone and suggests 10.4 nmol/L 
(300ng/dl) as the threshold to classify a patient as having a low total testosterone level.[26] 
However, the International Society of Andrology recommends 8.0 nmol/L (230ng/dl) as the 
threshold, whereas the American Association of Clinical Endocrinologists recommends 6.9 
nmol/L (200ng/dl) as the threshold for diagnosing males with hypogonadism.[27] The lack of 
consensus on the recommended testosterone threshold for low testosterone brings into 
question when a patient should be considered for testosterone replacement therapy (TRT).  
Although there are no generally accepted lower limits of normal levels, there is a general 
agreement that a total testosterone level above 12.0 nmol/L (350 ng/dl) does not require 
substitution. There is also consensus that patients with serum total testosterone levels below 
8.0 nmol/L (230 ng/dl) will usually benefit from testosterone replacement therapy.[21] If the 
serum total testosterone level is between 8.0 and 12.0 nmol/L, repeating the measurement of 
  
total testosterone with sex hormone-binding globulin (SHBG) to calculate free testosterone 
may be helpful.  
The serum sample for total testosterone determination should be obtained between 0700 and 
1100 h. Since there are known variations between assay methods, it is imperative that the 
practitioners use reliable laboratories and are acquainted with the reference ranges for 
testosterone for their specific laboratory. The measurement of free testosterone should be 
considered when the serum total testosterone concentration is not diagnostic of 
hypogonadism, particularly in obese men. There are no generally accepted lower limits of 
normal for free testosterone for the diagnosis of hypogonadism. However, a free testosterone 
level below 225 pmol/l (65 pg/ml) can provide supportive evidence for testosterone treatment. 
Measurements of serum LH will assist in differentiating between primary and secondary 
hypogonadism and serum prolactin is indicated when the serum testosterone is lower than 
5.2 nmol/l (150 ng/dl) or when secondary hypogonadism is suspected.  
Subsidiary diagnostic tools 
Validated questionnaires have been developed to assess symptoms associated with androgen 
deficiency, such as Aging Male Survey (AMS) and Androgen Deficiency in the Ageing Male 
(ADAM).[28] The AMS evaluates the severity of symptoms over time but is also designed to 
measure changes in symptoms before and after TRT.[29] The ADAM tool is designed to 
detect men at risk for androgen deficiency but it does not provide information about the 
severity of symptoms.[30] Although sensitive, these questionnaires have been shown to have 
low specificity. Morley et al. compared the most commonly used questionnaires in148 men 
using bioavailable testosterone (BT) as the bio-chemical ‘‘gold standard’’ for the diagnosis of 
hypogonadism, and found the sensitivity to be 97% for the ADAM and 83% for the 
AMS.[29] Specificity was 30% for the ADAM and 39% for the AMS. Despite having low 
specificity, the AMS and other male hypogonadism questionnaires may be useful to assess 
the presence and severity of symptoms and for monitoring the clinical response to TRT. 
 
Testosterone Replacement Therapy (TRT) 
TRT should be considered in men with symptoms of hypogonadism and low serum 
testosterone with the aim of restoring normal testosterone levels. Studies have demonstrated 
that in addition to restoring the normal level of testosterone, TRT improves body 
  
composition. Further benefits may include an increase in muscle mass as well as stabilisation 
of other endocrine functions.[31,32] In addition to physical and biomechanical benefits of 
TRT, a recent study reported a significant improvement in mood amongst opioid users after 
TRT.[33] Other long term and short term studies on hypogonadal men receiving TRT have 
also shown similar improvements in sexual function as well as improvements in symptoms of 
depression.[34,35] 
Kaergaard et al. suggested that patients with low testosterone levels could score higher on 
pain scores.[36] English et al. also suggested that low dose transdermal testosterone therapy 
may provide some analgesic effects.[37] A study conducted on 16 men on testosterone patch 
therapy suffering from opioid induced androgen deficiency (OPIAD) showed a substantial 
improvement in sexual function and mood.[14] Although many studies have found benefits in 
the use of TRT in patients suffering from opioid induced hypogonadism, not all studies have 
demonstrated positive outcomes. 
Huggins and Hodges identified a relationship between TRT and prostate cancer.[38] The 
authors reported that TRT was a contributing factor of the metastasis of prostate cancer to 
bone and that tumour growth rate was enhanced with the therapy. Several studies emerged 
shortly after which contradicted these findings. A systematic review by Shabsign et al. 
highlighted possible prostate cancer risk with TRT for hypogonadism.[39] In this systematic 
review, 11 placebo controlled and 29 non placebo controlled studies of men with no prostate 
cancer history and 4 studies of hypogonadal men with history of prostate cancer were 
included. The authors concluded that there was no evidence that testosterone replacement 
therapy increases the risk of prostate cancer in hypogonadal men.[39] In addition to this 
systematic review, a prospective study was conducted to evaluate the possible risk associated 
with sex hormones in serum and prostate cancer. This prospective study of 3886 men with 
prostate cancer and 6438 control subjects, examined the risk of prostate cancer based on 
serum concentration of sex hormones.[40] The findings of this study suggest that there was 
no association between serum concentration of sex hormones and the risk of prostate cancer. 
Although studies have concluded that there may be no risk of prostate cancer, we cannot 
neglect the fact that TRT may potentially cause adverse effects. Most common adverse 
effects appear to be acne and gynecomastia. However, recently developed testosterone 
therapy is alleged not to cause gynecomastia in patients.[41,42] Polycythaemia, an increase 
number of red blood cells, has also been linked with TRT.[43] It is thus recommended that 
  
haematocrit and haemoglobin concentration should be closely monitored in patients receiving 
TRT. 
DISCUSSION AND RECOMMENDATIONS 
Several studies have indicated that opioids result in low levels of testosterone and male 
hypogonadism regardless of the route of administration, i.e. whether oral, intrathecal or 
transdermal. Women appear to be also at risk of developing hypogonadism with menstrual 
irregularities, reduced libido and hot flushes.  
The main mechanism of opioid-induced hypogonadism appears to be suppression of GnRH 
resulting in low LH, FSH and sex hormones (secondary hypogonadism). In addition, there is 
evidence of impaired adrenal androgen production in women consuming opioids.[25] 
Despite this strong evidence, hypogonadism seems to be under diagnosed in patients treated 
with opioids. This may be due to under-reporting of symptoms by patients and also the lack 
of awareness by clinicians that hypogonadism is relatively common in this group of patients. 
Clinical diagnosis in men is hampered by the lack of specificity of assessment tools and the 
lack of consensus on the threshold of serum testosterone to diagnose hypogonadism. In 
women, symptoms of hypogonadism may go unrecognised or may be attributed to other 
conditions, such as depression. 
Untreated, low sex hormones can lead to osteopenia and osteoporosis in both men and 
women.[44,45] In men, the aim of treatment is to restore normal testosterone levels in order 
to improve quality of life, sense of well-being, sexual function, muscle strength and bone 
mineral density. 
 
We recommend that the potential effect of opioids on sex hormones should be clearly 
explained to patients before commencing treatment and patients should be advised to report 
symptoms which may be related to hypogonadism. We recommend measuring serum 
testosterone routinely in men treated with opioids and, if low, this should be confirmed by 
repeat measurement together with serum LH and FSH. If low serum testosterone is 
confirmed, we recommend assessment of bone mineral density and consideration of TRT. In 
women taking opioids, we recommend the measurement of serum oestradiol, LH and FSH in 
premenopausal women who develop menstrual irregularities. 
  
In conclusion, the use of opioids for the management of pain appears to be on the increase 
and the available evidence supports the notion that chronic opioid use can lead to 
hypogonadism. Clinicians should be aware of the symptoms and physical signs associated 
with hypogonadism. They should regularly monitor these patients with appropriate laboratory 
investigations and if hypogonadism is confirmed, hormone replacement therapy should be 
considered.  
  
  
MAIN MESSAGE 
 Long term opioid therapy may induce sexual dysfunction in men and women. 
 There is no consensus on the threshold in sex hormones in the diagnosis of 
hypogonadism. 
 Although subsidiary tools are valid in the diagnosis of low androgen levels, the 
precision and specificity are key issues in the use of these tools. 
 Replenishing testosterone with testosterone replacement therapy has been shown to 
improve testosterone levels in patients; however monitoring is essential to avoid risks 
of developing other complications. 
 
CURRENT RESEARCH QUESTIONS 
 Are different approaches to monitoring or treating hypogonadism associated with 
improved clinical outcomes? 
 Is there a dose-related association between opioid use and hypogonadism? 
 What is the best management option for patients with opioid-induced hypogonadism 
without disregard for their pain relief? 
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SELF ASSESSMENT QUESTIONS 
1. One of the characteristics of hypogonadism is low levels of testosterone. (True) 
2. Aging male survey is a valid questionnaire in measuring male androgen deficiency. 
(True) 
3. Testosterone replacement therapy does not aid in replenishing testosterone levels in 
hypogonadism patients. (False) 
4. Untreated low sex hormones can lead to osteopenia.(True) 
5. Symptoms of hypogonadism include decreased libido, impotence and fatigue.(True) 
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